Disc Medicine (IRON) Total Non-Current Liabilities (2020 - 2023)
Disc Medicine (IRON) reported Total Non-Current Liabilities of $16.0 million for Q3 2023, up 994.47% year-over-year from $1.5 million in Q3 2022, and up 39.88% quarter-over-quarter from $11.5 million in Q2 2023.
Disc Medicine (IRON) Total Non-Current Liabilities (2020 - 2023) Analysis & Trends
Disc Medicine (IRON) has 4 years of Total Non-Current Liabilities data on file, last reported at $16.0 million in Q3 2023.
- Total Non-Current Liabilities for Q3 2023 came in at $16.0 million, up 994.47% year-over-year; the trailing twelve-month figure through Sep 2023 was $16.0 million (up 994.47% YoY), and the FY2022 annual result was $23.6 million, up 76.71% from the prior year.
- Total Non-Current Liabilities improved to $16.0 million in Q3 2023 per IRON's latest filing, from $11.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $29.9 million in Q4 2020 and troughed at -$76000.0 in Q1 2020.
- A 4-year average of $12.9 million and a median of $13.4 million in 2021 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities surged 23659.21% in 2021, then slumped 89.77% in 2022.
- A 4-year view of Total Non-Current Liabilities shows it stood at $29.9 million in 2020, then slumped by 55.33% to $13.4 million in 2021, then soared by 76.71% to $23.6 million in 2022, then tumbled by 32.12% to $16.0 million in 2023.
- Business Quant data shows IRON's Total Non-Current Liabilities at $16.0 million in Q3 2023, $11.5 million in Q2 2023, and $23.6 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Disc Medicine | 2.73 Bn | 2.00 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 16.02 Mn |
| Jun 30, 2023 | 11.46 Mn |
| Dec 31, 2022 | 23.61 Mn |
| Sep 30, 2022 | 1.46 Mn |
| Jun 30, 2022 | 6.44 Mn |
| Mar 31, 2022 | 12.67 Mn |
| Dec 31, 2021 | 13.36 Mn |
| Sep 30, 2021 | 14.31 Mn |
| Jun 30, 2021 | 14.39 Mn |
| Mar 31, 2021 | 17.91 Mn |
| Dec 31, 2020 | 29.90 Mn |
| Jun 30, 2020 | 6.55 Mn |
| Mar 31, 2020 | -76,000.00 |